Revolutionary study on leukeman treatment: hope for 400 patients!

Revolutionary study on leukeman treatment: hope for 400 patients!

Universitätsmedizin Mainz, 55131 Mainz, Deutschland - Today, on May 28, 2025, Phase III Study Evolve II for the treatment of acute myeloid leukemia (AML) was heralded. This significant research initiative is by the III. Medical clinic of the University Medical Center Mainz and aims to test a combination of medication for better containment of the AML. Around 400 patients are to participate in the study: which underlines the urgency and the potential of these research efforts. On the occasion of the World blood cancer day, the importance of this study has been particularly emphasized, since AML represents an aggressive form of blood cancer that is often fatal without treatment.

The standard of treatment at AML has been chemotherapy since 1973, but only about half of the patients can be healed permanently. Always recent knowledge, since 2008, have shown that at least two molecular mechanisms are involved in the development of the AML, which has triggered new research efforts to identify therapeutic goals. The Evolve II study is testing a combination of revums, a menin inhibitor, venetoclax and azacitidine. This combination promises promising results in the therapy of AML, which is characterized by various mutagenetic features.

research framework and support

The Evolve II study is supported by over 150 centers from 18 countries and is part of the Collaborative Research Center 1292 to influence immunity in tumor diseases. The sponsors include the Dutch Hovon study group as well as the German-Austrian AML study group (AMLSG) and the UK Clinical Trials Group. The financing is carried out by Syndax. Professor Michael Kühn took over the management at the German-Austrian centers.

In addition to the Evolve II study, the treatment of acute myeloid leukemia is intensively examined. A far -ranging Germany -wide analysis shows that, at medium risk, an immediate stem cell transplantation during the first complete remission does not necessarily lead to better overall survival, compared to continued chemotherapy and a later transplant in the event of a relapse. This study, which is led by University Medicine Dresden and the Westphalian Wilhelms-Universität Münster, offers new perspectives in AML treatment and has the potential to fundamentally influence therapy decisions.

Current challenges and developments

In the past ten years, AML management has improved significantly, which is reflected in better diagnoses and new therapy approaches. Despite the progress, the forecast for many patients remains cloudy; Only about 30% of adult AML patients survive at least five years after the diagnosis. Understanding the disease has developed significantly through new therapeutic options that have been on the market since 2017. Diseased patients are increasingly benefiting from personalized therapy strategies that are tailored to their respective clinical profiles.

The latest developments in treatment enable targeted risk assessment and improved monitoring of the course of the disease. With the introduction of new therapy approaches, such as the combination of Venetoclax with hypomethylating aggressors for older patients or those who are not suitable for intensive therapies, the perspectives have become more promising for the patients.

Further information on the current developments in AML treatment can be found in the articles of pmc , and University Medical Center Münster .